Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $20.3333.

ENTA has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. Finally, JPMorgan Chase & Co. assumed coverage on shares of Enanta Pharmaceuticals in a report on Friday, November 14th. They issued an “overweight” rating and a $17.00 target price on the stock.

Enanta Pharmaceuticals Stock Performance

ENTA stock opened at $14.25 on Thursday. The stock’s 50 day simple moving average is $14.11 and its 200 day simple moving average is $11.41. The company has a market cap of $413.54 million, a P/E ratio of -4.45 and a beta of 0.98. Enanta Pharmaceuticals has a fifty-two week low of $4.09 and a fifty-two week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12. Enanta Pharmaceuticals had a negative return on equity of 78.58% and a negative net margin of 106.80%.The firm had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. Equities analysts predict that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Insider Transactions at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly sold 4,743 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $67,492.89. Following the transaction, the chief executive officer owned 858,026 shares in the company, valued at $12,209,709.98. This trade represents a 0.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tara Lynn Kieffer sold 2,106 shares of the company’s stock in a transaction on Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the sale, the insider owned 30,620 shares of the company’s stock, valued at $435,722.60. This trade represents a 6.44% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 11,961 shares of company stock valued at $170,149 over the last ninety days. 11.48% of the stock is currently owned by insiders.

Institutional Trading of Enanta Pharmaceuticals

Several institutional investors have recently made changes to their positions in ENTA. CWM LLC lifted its position in shares of Enanta Pharmaceuticals by 22.1% during the 2nd quarter. CWM LLC now owns 21,464 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 3,879 shares during the last quarter. Bank of Montreal Can lifted its holdings in Enanta Pharmaceuticals by 32.8% during the second quarter. Bank of Montreal Can now owns 33,868 shares of the biotechnology company’s stock valued at $256,000 after purchasing an additional 8,365 shares during the last quarter. Strs Ohio purchased a new stake in Enanta Pharmaceuticals during the fourth quarter valued at about $50,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Enanta Pharmaceuticals by 333.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 2,758 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new position in shares of Enanta Pharmaceuticals in the third quarter worth about $125,000. Institutional investors own 94.99% of the company’s stock.

Key Headlines Impacting Enanta Pharmaceuticals

Here are the key news stories impacting Enanta Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $20 price target (roughly ~40% upside vs. current levels), supporting investor confidence in Enanta’s longer‑term value. Benzinga coverage of analyst action
• Positive Sentiment: Q1 snapshot showed an EPS and revenue beat (reported EPS -$0.42 vs. -$0.54 expected; revenue ~$18.6M vs. ~$16.1M expected), a near‑term operational positive that likely helped lift the shares. Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot
• Positive Sentiment: HC Wainwright raised several near‑term and multi‑year EPS forecasts (Q2 & Q3 2026 moved to -$0.51 from -$0.54; FY2027–FY2030 estimates nudged slightly less negative), indicating the analyst sees modest improvement in the company’s outlook.
• Neutral Sentiment: Media/coverage note: articles analyzing the move (including one explaining a ~6% intraday rise) are circulating, reflecting heightened investor interest but not new company announcements. Why Enanta Pharmaceuticals, Inc.’s (ENTA) Stock Is Up 5.97%
• Neutral Sentiment: Short‑interest data published for February appears anomalous (reported as 0 shares / NaN change). That data point is unreliable and should not be treated as a directional signal until clarified by exchanges/reporting sources.
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS estimate to -$0.73 from -$0.56, a meaningful pullback for that quarter which could weigh on near‑term sentiment if risks persist into later 2026.
• Negative Sentiment: Despite tweaks, the company remains unprofitable on consensus metrics (current full‑year consensus around -$4.65 EPS); continued negative earnings and cash‑burn/clinical risk remain key downside drivers for the stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.